key: cord-0979980-trvecxvs
authors: Mandal, Amit.K.J.; Wenban, Charlotte; Heer, Randeep S.; Kho, Jason; Missouris, Constantinos G.
title: Covid-19, hypokalaemia and the renin-angiotensin-aldosterone system
date: 2021-03-27
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2021.102261
sha: a98ca8dae5583c66b44c6f61d856a961ede7c2b0
doc_id: 979980
cord_uid: trvecxvs

nan

week. Plasma renin and aldosterone were found normal after three weeks and amiloride was withdrawn. Thereafter the patient remained normotensive with a normal biochemical profile during recovery [2] .

The diuretic amiloride inhibits sodium reabsorption by selectively blocking the sodium channel (ENaC) in the distal nephron [3, 4] and hyporeninaemic hypoaldosteronism may be related to temporary dysregulated ENaC pathophysiology similar to that in Liddle's syndrome. Stabilisation of the renin-angiotensin-aldosterone system (RAAS) and distal tubulopathy (evident by reduction in renal potassium excretion) during convalescence supports a direct effect of SARS-CoV-2 on ENaC homeostasis. This is supported by the findings of Chen et al [5] . The ongoing potassium loss described by Alnafie et al. may signify prolonged RAAS disruption and tubulopathy resulting in a 'long Covid hypokalaemia' syndrome. It would be of interest if Alnafie and colleagues were able to demonstrate and quantify ongoing renal wastage. It should be noted that hypomagnesaemia exacerbates hypokalaemia by increasing distal potassium secretion and renders it refractory to treatment; thus, each state may feed each other in a vicious circle.

The phenomenon (that we reported) may be adequately explained by downregulation of angiotensin converting enzyme 2 (ACE2) from viral binding resulting in upregulation of angiotensin 2 (ang 2) which enhances ENaC activity [6] . It has also been mentioned that accumulation of ang 2 may induce aldosterone secretion by the adrenal cortex leading to sodium reabsorption and potassium excretion from the collecting duct in kidney [7] .

Although there is clearly a complex interplay between viral-ACE 2 binding and the RAAS with various ramifications, we suggest an "aldosterone-independent" process may be a principal underlying mechanism. Hyporeninaemic hypoaldosteronism reflects appropriate and intact RAAS homeostatic mechanisms in the face of hypertension and hypokalaemia.

Confounding factors, such as gastrointestinal losses, nutritional insufficiencies and drug-related renal potassium loss may muddy the waters leaving this metabolic profile overlooked in Covid-19 patients, and it must also be acknowledged that there could be considerable overlap in aetiologies of hypokalaemia. However, disruption of the RAAS may 

Persistent Hypokalemia post SARS-coV-2 infection, is it a life-long complication? Case report

Covid-19 and late onset hypertension with hyorininaemic hypoladosteronism

Membrane topology of the amiloride-sensitive epithelial sodium channel

Liddle's syndrome mechanisms, diagnosis and management

Direct activation of ENaC by angiotensin II: recent advances and new insights

Assessment of Hypokalemia and Clinical Characteristics in Patients With Coronavirus Disease

Multifaceted persistent hypokalaemia in a patient with coronavirus disease

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.Please state any conflicts of interest All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.No financial or personal conflicts of interest for any author.

Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.Written and signed consent was obtained from the patient discussed.J o u r n a l P r e -p r o o f

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.